Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000000838
Abstract: Anthracycline-induced cardiotoxicity remains a significant contributor to late morbidity/mortality in children and young adults with acute myeloid leukemia (AML). The cardioprotectant dexrazoxane can be used as prophylaxis to diminish risk for cardiomyopathy but whether it… read more here.
Keywords: children young; adults acute; oncology; aml ... See more keywords
Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002538
Abstract: Introduction: Doxorubicin leads to dose dependent cardiotoxicity in childhood acute lymphoblastic leukemia (ALL) survivors. We investigated survivors’ heart health using echocardiography and evaluated doxorubicin and dexrazoxane treatments on cardiac function. Methods: A total of 196… read more here.
Keywords: oncology; childhood acute; childhood; dexrazoxane ... See more keywords
Evaluation of dexrazoxane effect on preventing acute cardiac arrhythmia in patients with breast cancer treated with neoadjuvant/adjuvant anthracycline‐based chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Practice"
DOI: 10.1111/ijcp.14705
Abstract: Adding dexrazoxane to the treatment during neoadjuvant/adjuvant anthracycline‐based chemotherapy in patients with breast cancer prevents the development of heart failure. In this study, we investigated whether dexrazoxane has a protective effect on arrhythmia resulting from… read more here.
Keywords: patients breast; neoadjuvant adjuvant; adjuvant anthracycline; based chemotherapy ... See more keywords
Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma
Sign Up to like & getrecommendations! Published in 2019 at "Open Heart"
DOI: 10.1136/openhrt-2019-001025
Abstract: Objective We sought to determine how sex and dexrazoxane therapy influence cardiac remodelling in children with sarcoma receiving high-dose doxorubicin. Methods In a retrospective cohort of 85 children with sarcoma receiving high-dose doxorubicin, echocardiography measures… read more here.
Keywords: children sarcoma; cavity size; dexrazoxane; high dose ... See more keywords
Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p
Sign Up to like & getrecommendations! Published in 2020 at "BioMed Research International"
DOI: 10.1155/2020/5107193
Abstract: The usage of doxorubicin is hampered by its life-threatening cardiotoxicity in clinical practice. Dexrazoxane is the only cardioprotective medicine approved by the FDA for preventing doxorubicin-induced cardiac toxicity. Nevertheless, the mechanism of dexrazoxane is incompletely… read more here.
Keywords: doxorubicin induced; apoptosis; treatment; group ... See more keywords
Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"
Sign Up to like & getrecommendations! Published in 2018 at "Circulation Research"
DOI: 10.1161/circresaha.118.312921
Abstract: We thank Dr Lipshultz for pointing out an error in our characterization of the European Medicines Agency action on the use of dexrazoxane as a cardioprotective agent for patients receiving anthracycline chemotherapy.1 One of the… read more here.
Keywords: european medicines; medicines agency; cardiotoxicity; letter ... See more keywords
Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.02423
Abstract: PURPOSE For survivors of childhood cancer treated with doxorubicin, dexrazoxane is cardioprotective for at least 5 years. However, longer-term data are lacking. METHODS Within the Children's Oncology Group and the Dana Farber Cancer Institute's Childhood… read more here.
Keywords: survivors childhood; function; doxorubicin; dexrazoxane ... See more keywords
Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
Sign Up to like & getrecommendations! Published in 2018 at "Future oncology"
DOI: 10.2217/fon-2018-0210
Abstract: Dexrazoxane can prevent anthracycline-associated cardiotoxicity. However, in 2011, its use in children was contraindicated by the EMA over concerns of increased risk of infection, myelosuppression and second primary malignancies, and because its efficacy in children… read more here.
Keywords: risk; anthracycline; risk benefit; cardiotoxicity ... See more keywords